SCHEMBL14745337

SCHEMBL14745337

CC/C(=N/Cc1ccc(OC)cc1OC)c1ccc2c(c1)cc(CO[Si](C)(C)C(C)(C)C)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
PKM P14618 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MAPT P10636 4/20 0.32
LMNA P02545 4/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HSD17B10 Q99714 2/20 0.32
HTT P42858 2/20 0.32
TSHR P16473 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
TP53 P04637 1/20 0.31
PPARG P37231 1/20 0.31
GAA P10253 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745339 1.00 NPC1 (0.33) NPC1RAB9APKMMAOAMAOB
SCHEMBL14741007 0.93 NPC1 (0.33) NPC1RAB9APKMMAOAMAOB
SCHEMBL16428739 0.93 NPC1 (0.33) NPC1RAB9APKMMAOAMAOB
SCHEMBL14745030 0.88 NPC1 (0.35) NPC1RAB9APKMMAOAMAOB
SCHEMBL14745032 0.88 NPC1 (0.35) NPC1RAB9APKMMAOAMAOB
SCHEMBL16428689 0.85 MAPT (0.32) NPC1RAB9APKMMAOAMAOB
SCHEMBL14741305 0.85 MAPT (0.32) NPC1RAB9APKMMAOAMAOB
SCHEMBL14746205 0.77 MAPT (0.33) NPC1RAB9APKMMAPTTP53
SCHEMBL14746204 0.77 MAPT (0.33) NPC1RAB9APKMMAPTTP53
SCHEMBL16428704 0.75 NPC1 (0.33) NPC1RAB9APKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP NPC1 1233/4885RAB9A 1346/4885PKM 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.